Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to examine the wound infusion of articaine for treatment of acute post-sternotomy pain in a placebo-controlled manner using a prospective and randomized design and an active control (bupivacaine)


Clinical Trial Description

Acute pain after open heart surgery can be moderate or strong and is mostly caused by sternotomy. Pain is the worst during the first two post-operative days and, if not adequately treated, can delay the patient´s recovery from surgery. Sternotomy pain can be alleviated by using paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. All these drugs may have remarkable side-effects which may delay the recovery from surgery: opioids are respiratory depressants and slower the gastrointestinal motility, NSAIDs reduce intrarenal blood flow and may disturb coagulation. Post-operative opioid consumption can be reduced by using wound infiltration analgesia.

The use of wound infiltration analgesia has not been extensively investigated in treatment of acute pain after sternotomy. There is some evidence, that 0.5% bupivacaine reduces the acute post-sternotomy pain when infused constantly via catheters placed under the fascia (periosteal placement) and the skin.

During 48 hours infusion toxic bupivacaine plasma levels were not observed. There is an evidence that local anesthetics can be bacteriostatic both in vitro and in vivo.

Articaine is an amide-type local anesthetics, which has been used extensively in dental procedures since more than forty years. It has been successfully used in infiltration, epidural, spinal and other regional anesthesia procedures. Articaine is quickly hydrolyzed in plasma and excreted by kidneys. Clearance of articain (500-1110l/h) is faster than that of lidocaine (68l/h) and it is also the reason for articaine´s low toxicity profile. Because of it´s low toxicity and high ability to penetrate the periosteal tissue, articaine may be advantageous in treatment of acute pain after sternotomy, but aforementioned indication for use of articaine has not been investigated. Compared to other local anesthetics, articaine in high concentration has the same neurotoxicity profile, when injected directly into rat´s sciatic nerve. Articaine has not been extensively compared to other local anesthetics, but according the latest odontologic investigation, single dose 0.5% bupivacaine and single-dose 4% articaine were comparable in their analgesic effects during tooth extraction procedure. There are no controlled randomized trials comparing analgesic effect of articaine and other local anesthetics infusions.

In our investigation bupivacain 0.5 % was chosen as an active control, because it has appeared effective in acute postoperative pain and it has reduced the need for opioid analgetics after sternotomy ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01536717
Study type Interventional
Source Helsinki University Central Hospital
Contact
Status Suspended
Phase Phase 4
Start date March 2012
Completion date December 2022

See also
  Status Clinical Trial Phase
Completed NCT02910349 - Novel Cardiac Imaging Prognostic Markers of Clinical Outcome in Patients With Chronic Aortic Regurgitation
Completed NCT03298932 - 2D Strain of Right Ventricle in Peroperative of Cardiac Surgery
Completed NCT01171625 - Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX N/A
Completed NCT01959503 - Progel Vascular Sealant N/A
Completed NCT01353287 - Transcatheter Aortic Valve Intervention-Live Transmission N/A
Completed NCT03016169 - Trifectaâ„¢ GT Post Market Clinical Follow-up N/A
Terminated NCT02678871 - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage N/A
Completed NCT00934596 - CO2 Versus Lund De-airing Technique in Heart Surgery N/A
Completed NCT01651052 - Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000 N/A
Terminated NCT02696226 - Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement. N/A
Completed NCT01619982 - Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients Phase 4